Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
AstraZeneca PLC American Depositary Shares
AZN
$201.21 (- $2.99 - 1.46%)
Last updated: Previous Close (2026-04-15)
About the Company
AstraZeneca PLC American Depositary Shares represent ownership in AstraZeneca PLC, a multinational biopharmaceutical company headquartered in Cambridge, United Kingdom. The company focuses on the discovery, development, manufacture, and commercialization of prescription medicines across key therapeutic areas. Oncology constitutes its largest segment, featuring products like Tagrisso, Imfinzi, Calquence, Enhertu, and Truqap. Other core areas include cardiovascular, renal, and metabolic medicines such as Farxiga and Brilinta; rare disease therapies like Ultomiris and Soliris; and respiratory and immunology treatments including Symbicort, Fasenra, and Breztri. AstraZeneca PLC also offers vaccines and immune therapies. It serves primary and specialty care physicians globally through distributors and local offices, with significant presence in the United States, Europe, and Asia. This structure positions AstraZeneca PLC as a major player in the global pharmaceutical industry, addressing diverse medical needs in oncology, rare diseases, and chronic conditions.
Price History
Latest News for AZN
ULTOMIRIS Sales Forecast and Market Size Analysis Report 2026-2034 with Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan
Ultomiris offers major market opportunities through its long-acting C5 inhibition, leading to significant patient convenience and compliance with fewer infusions. Rapid conversion from older therapies and expanding regulatory approvals across multiple rare diseases enhance market penetration. Its strong sales growth and expansion into neurology and nephrology further solidify its position.Dublin, May 15, 2026 (GLOBE NEWSWIRE) -- The "ULTOMIRIS Sales Forecast and Market Size Analysis - 2034" has
European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading
European equities traded in the US as American depositary receipts were moving higher late Thursday
Perioperative IMFINZI® (durvalumab) plus neoadjuvant EV showed statistically significant and clinically meaningful improvements in event-free survival and overall survival in muscle-invasive bladder cancer in the Phase III VOLGA trial
WILMINGTON, Del., May 14, 2026--High-level results from a planned interim analysis of the VOLGA Phase III trial showed perioperative treatment with IMFINZI® (durvalumab) in combination with neoadjuvant enfortumab vedotin (EV) demonstrated statistically significant and clinically meaningful improvements in event-free survival (EFS) and overall survival (OS) in patients with muscle-invasive bladder cancer (MIBC) versus standard of care. Patients were ineligible for or had declined cisplatin-based
Owkin Expands AstraZeneca Collaboration Around K Pro AI Platform
Agentic AI company Owkin said it signed a three-year licensing agreement with AstraZeneca Plc. (NASDAQ:AZN) to develop specialized biopharma AI agents using its K Pro platform, expanding the companies' existing collaboration in drug discovery and development. The agreement will allow Owkin to build end-to-end AI agents designed to operate within AstraZeneca's internal infrastructure and decision-making workflows. The companies said the tools are intended to support competitive intelligence and p
Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?
Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.
Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback?
Wondering if AstraZeneca at £137.48 is offering fair value or if the price is running ahead of itself? This article walks through what the current valuation signals might mean for you. The stock is up 3.1% over the past week, while the past month shows a decline of 9.7%, with returns of 1.1% year to date and 37.4% over the last year, 20.9% over three years and 92.6% over five years. Recent headlines around AstraZeneca have focused on its role as a major global pharmaceuticals player, with...